Peptide record

TPDB20580

Antibacterial Antiviral Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB20580
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia, AI4AVP, dbAMP 3.0, and other sources, with an available 3D structural model.
Sequence
GRFKRFRKPFKKLFKKIS
Physicochemical Analysis
C112H183N33O20
ANDCEQHMTWYV
K
2311.89
12.72
9
0
6
+9
3.57
-1.122
43.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
1
I
1
L
6
K
0
M
4
F
1
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 1 K: 6 M: 0 F: 4 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18
C112H183N33O20
2311.89
12.72
+9
3.57
-1.122
Evidence Records 4 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

NA

Other

inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.2 uM).
Evidence 2 Activity

Activity

Antiviral

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.2 uM).
Evidence 3 Activity

Activity

50% cell death
Toxicity
18.9 µM
Cytotoxic
50% cell death | 18.9 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.18591279]CEM-SS cells:TC50=18.9 µM.(TC50:the concentration that reduced cell viability by 50%)

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2008 Sep 52(9):3438-40.